about
Identification of a novel IGH-MMSET fusion transcript in a human myeloma cell line with the t(4;14)(p16.3;q32) chromosomal translocationImmune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptors.Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia.Intraclonal cell expansion and selection driven by B cell receptor in chronic lymphocytic leukemia.Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia.Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia.Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders.A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias.Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma.Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia.Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line.EGFR through STAT3 modulates ΔN63α expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas.Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.Anagrelide and Mutational Status in Essential Thrombocythemia.Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles.CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL.Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.Molecular and transcriptional characterization of the novel 17p11.2-p12 amplicon in multiple myeloma.Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma.Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma.Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia.Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study.Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma.Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome.Differential repetitive DNA methylation in multiple myeloma molecular subgroups.High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation.Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation.Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia.A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect.Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion.Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma.Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study.Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.IgV gene intraclonal diversification and clonal evolution in B-cell chronic lymphocytic leukaemia.Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.
P50
Q28272420-CDFE6ECF-2A42-4745-8061-21B3ABDCFA54Q33399624-CEF2BE00-F6C2-4E3E-A184-65D624D1BBFCQ34978154-B2FD98EF-C132-4578-B64C-F89B678A039CQ35136742-C680F23B-B412-4140-815A-640053EAB13BQ35140580-BDC2F04A-1DE2-4323-BE4C-5436DC769174Q35192691-396F55D8-217D-4E18-A4CB-622CBE2FF247Q36133050-C2FDDBFE-D77F-44DA-BC94-924359AA7E2CQ36413387-67350DEB-A6A2-49A4-87E1-948589D03C27Q36414422-5C6F6925-D835-4C13-B971-1B68A6B6974BQ36439245-691B2AFC-00FB-4699-BC11-1B1C3C5187E2Q37179155-1854CC6A-142F-4803-9E28-91053828C67DQ39044553-3EF24A0A-4ADF-40AD-BB28-D088F24E01A7Q39270164-672007A1-6006-4D55-A5BB-70B848DDE870Q39430844-D1611A2F-DDB3-4495-AB68-6940213E61CBQ39867043-5089BBA8-69D9-4B14-BF28-76A9D48E4888Q39869539-0F44B602-0667-4FDC-AE7F-B5F6C96753DFQ39999150-2D39043B-A81A-485E-A2E4-C526801BA15CQ40002181-E0E2C10F-1903-4BEA-8D07-4F26CADEAA97Q40083717-BFB4F805-9242-4860-99D0-DEA1814999B0Q40195859-7B85043F-2FDC-432A-9B9C-FB82E29FE810Q40220950-63675B93-9DD5-4C7D-A63B-E2127FC9CED1Q40646030-A4240C38-BC20-4A12-AE84-FD0679EA40DBQ41092333-ED8DF037-3DAF-4C0B-9AE8-21F2790F6F48Q42627572-A9A7C05E-5C2E-4ED3-AD15-9112F113842DQ44447816-12DC625D-DDE7-4B2A-9A29-9EF299437B22Q45181930-A48BCB2E-290E-4BB6-9DDF-B44123349867Q45330340-CA2979AA-8379-4BA0-826B-47B74EFAAB06Q45392132-6FB5C799-FACC-4714-8E1B-27114A12A73CQ45966859-25244151-1945-464E-ADBE-648CE71ECAA0Q46444068-D53E1A35-DA32-485E-BED6-59CC7A13D48FQ47620411-CACCB139-67A6-48B7-82F0-48DF30ABE12FQ47715295-42820361-238C-4D45-B932-EBF40C00EDF4Q47812640-BFF88D37-A974-49BC-A6A7-05E0FBAC0EB8Q47934995-B4BC18C3-3793-4B34-87FA-6B1C25B792BCQ51647676-C5BB2094-A9BD-4706-9D0B-CACF4172D6D1Q53766891-7376075E-5C2A-4B91-BA84-1952E20CE59FQ54323411-D902EDE5-EFED-4CB4-92D3-52625FB615E9Q54409071-64BA983B-A73A-4131-AB61-7C874176BD76Q54615575-B4409E50-8884-441D-9DD5-B0F5007F5C9BQ54646402-0573B7CC-028C-4334-A429-DE33ABE4AEC0
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Sonia Fabris
@ast
Sonia Fabris
@en
Sonia Fabris
@es
Sonia Fabris
@nl
Sonia Fabris
@sl
type
label
Sonia Fabris
@ast
Sonia Fabris
@en
Sonia Fabris
@es
Sonia Fabris
@nl
Sonia Fabris
@sl
prefLabel
Sonia Fabris
@ast
Sonia Fabris
@en
Sonia Fabris
@es
Sonia Fabris
@nl
Sonia Fabris
@sl
P214
P106
P1153
6603787313
P21
P214
P31
P396
IT\ICCU\BVEV\178531
P496
0000-0003-1341-0503
P569
1969-01-01T00:00:00Z
P735
P7859
viaf-307326379